Goldman Sachs’s Ironwood Pharmaceuticals IRWD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.44M Buy
2,690,634
+1,415,319
+111% +$5.8M ﹤0.01% 3119
2025
Q4
$4.3M Buy
1,275,315
+190,948
+18% +$496K ﹤0.01% 3885
2025
Q3
$1.42M Sell
1,084,367
-360,363
-25% -$373K ﹤0.01% 4770
2025
Q2
$1.04M Sell
1,444,730
-130,686
-8% -$103K ﹤0.01% 4669
2025
Q1
$2.32M Buy
1,575,416
+660,144
+72% +$1.57M ﹤0.01% 4029
2024
Q4
$4.05M Sell
915,272
-307,865
-25% -$1.25M ﹤0.01% 3660
2024
Q3
$5.04M Sell
1,223,137
-340,295
-22% -$1.83M ﹤0.01% 3336
2024
Q2
$10.2M Buy
1,563,432
+183,770
+13% +$1.3M ﹤0.01% 2484
2024
Q1
$12M Buy
1,379,662
+297,997
+28% +$3.62M ﹤0.01% 2315
2023
Q4
$12.4M Sell
1,081,665
-24,904
-2% -$246K ﹤0.01% 2332
2023
Q3
$10.7M Buy
1,106,569
+112,105
+11% +$1.1M ﹤0.01% 2336
2023
Q2
$10.6M Sell
994,464
-82,833
-8% -$890K ﹤0.01% 2398
2023
Q1
$11.3M Buy
1,077,297
+59,169
+6% +$663K ﹤0.01% 2303
2022
Q4
$12.6M Sell
1,018,128
-390,589
-28% -$4.43M ﹤0.01% 2372
2022
Q3
$14.6M Buy
1,408,717
+416,590
+42% +$4.72M ﹤0.01% 2145
2022
Q2
$11.4M Sell
992,127
-1,625,784
-62% -$19.2M ﹤0.01% 2387
2022
Q1
$32.9M Sell
2,617,911
-693,230
-21% -$7.95M 0.01% 1649
2021
Q4
$38.6M Buy
3,311,141
+235,865
+8% +$2.89M 0.01% 1554
2021
Q3
$40.2M Buy
3,075,276
+43,705
+1% +$565K 0.01% 1450
2021
Q2
$39M Buy
3,031,571
+1,450,335
+92% +$16.6M 0.01% 1476
2021
Q1
$17.7M Sell
1,581,236
-581,872
-27% -$6.15M ﹤0.01% 2038
2020
Q4
$24.6M Buy
2,163,108
+1,055,370
+95% +$11.5M 0.01% 1682
2020
Q3
$9.96M Sell
1,107,738
-54,238
-5% -$539K ﹤0.01% 2327
2020
Q2
$12M Buy
1,161,976
+388,915
+50% +$3.98M ﹤0.01% 2127
2020
Q1
$7.8M Sell
773,061
-575,937
-43% -$6.77M ﹤0.01% 2278
2019
Q4
$18M Buy
1,348,998
+316,575
+31% +$3.49M ﹤0.01% 1960
2019
Q3
$8.86M Buy
1,032,423
+231,208
+29% +$2.25M ﹤0.01% 2410
2019
Q2
$8.77M Sell
801,215
-1,234,362
-61% -$13.8M ﹤0.01% 2467
2019
Q1
$23.1M Buy
2,035,577
+7,672
+0.4% +$85.7K 0.01% 1750
2018
Q4
$17.6M Buy
2,027,905
+662,469
+49% +$7.6M 0.01% 1910
2018
Q3
$21.1M Buy
1,365,436
+245,150
+22% +$3.88M 0.01% 1869
2018
Q2
$17.9M Buy
1,120,286
+143,824
+15% +$2.13M ﹤0.01% 1960
2018
Q1
$12.6M Buy
976,462
+439,205
+82% +$5.47M ﹤0.01% 2165
2017
Q4
$6.75M Buy
537,257
+323,736
+152% +$4.23M ﹤0.01% 2755
2017
Q3
$2.82M Sell
213,521
-739,837
-78% -$10.2M ﹤0.01% 3674
2017
Q2
$15.1M Sell
953,358
-299,744
-24% -$4.36M ﹤0.01% 2186
2017
Q1
$17.9M Sell
1,253,102
-71,692
-5% -$980K ﹤0.01% 1965
2016
Q4
$17M Sell
1,324,794
-294,434
-18% -$3.72M ﹤0.01% 2076
2016
Q3
$21.5M Buy
1,619,228
+1,179,344
+268% +$13.8M 0.01% 1830
2016
Q2
$4.82M Buy
439,884
+212,697
+94% +$2.08M ﹤0.01% 2902
2016
Q1
$2.08M Buy
227,187
+92,895
+69% +$766K ﹤0.01% 3429
2015
Q4
$1.3M Sell
134,292
-67,082
-33% -$648K ﹤0.01% 4038
2015
Q3
$1.76M Sell
201,374
-491,620
-71% -$4.59M ﹤0.01% 3927
2015
Q2
$7M Buy
692,994
+263,033
+61% +$3.06M ﹤0.01% 2650
2015
Q1
$5.76M Sell
429,961
-473,046
-52% -$6.21M ﹤0.01% 2763
2014
Q4
$11.6M Buy
903,007
+442,602
+96% +$5.07M ﹤0.01% 2234
2014
Q3
$5M Sell
460,405
-256,689
-36% -$2.94M ﹤0.01% 3020
2014
Q2
$9.21M Sell
717,094
-11,715
-2% -$127K ﹤0.01% 2433
2014
Q1
$7.52M Buy
728,809
+564,732
+344% +$6.35M ﹤0.01% 2616
2013
Q4
$1.6M Buy
164,077
+99,927
+156% +$897K ﹤0.01% 4304
2013
Q3
$636K Sell
64,150
-172,929
-73% -$1.7M ﹤0.01% 4973
2013
Q2
$1.97M Buy
+237,079
New +$2.87M ﹤0.01% 3750

Other funds holding IRWD

Goldman Sachs's IRWD Position: Q1 2026 in Review

Goldman Sachs increased its Ironwood Pharmaceuticals (IRWD) stake by 111% in Q1 2026, buying an estimated $5.8M and bringing the position to 2,690,634 shares worth $9.44M. The position accounts for ﹤0.01% of the portfolio, ranked #3119.

Goldman Sachs first reported a position in IRWD in Q2 2013 and has held it in 52 quarters since. The position peaked at $40.2M in Q3 2021. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

  • Goldman Sachs held 2,690,634 shares of Ironwood Pharmaceuticals worth $9.44M as of Q1 2026.
  • Goldman Sachs bought 1,415,319 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $5.8M.
  • Ironwood Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3119 holding.
  • Goldman Sachs first reported a position in Ironwood Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Ironwood Pharmaceuticals position peaked at $40.2M in Q3 2021.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.